Head: Dr. Claudio Botti, MD
STAFF

• Main research lines:
• Identification of signature responsiveness to innovative drugs
• Identification of new imaging techniques in senology (CESM)
• Indocyanine green as a unique method for sentinel lymph node biopsy after neoadjuvant chemotherapy.
• Innovative technical application of conservative volume replacement oncoplasty by fascio--adipose propeller flaps set up by microsurgical anatomical dissection
• Development of personalized algorithm of breast reconstruction after mastectomy (optimize do not compromise)
• Precision surgery approach to generate living biobank (organoid) from primary breast cancer, metastases, adjacent tissues and benign tumors in order to identify innovative molecular vulnerabilities of metastatic disease and markers of early tumor progression

Collaborative studies ongoing:

• Prospective validation of TAZ score as a pathological complete response biomarker in patients with luminal B / HER2 positive breast cancer treated with trastuzumab based neo adjuvant therapy TRISKELE Trial
• Impact of expression of Hippo pathway components in patients with breast cancer treated or candidate for neoadjuvant chemotherapy
• Efficacy and Tolerability of Cario Patient Neopardive Chemotherapy in Patients with Triple Negative Breast Cancer: Multicenter Observational Study. NeoCarbo study
• Predictidicve / Prognostic Biomarkers IdentificaMon in Triple Negative Breast Cancer. NeoTAZ study
• TAZ as a prognostic biomarker in patients with early breast cancer. PHOBOS Trial
• Atorvastatin vs Observation in Patients with Initial Breast Cancer with High Ki‐67 and Positivity for TAZ: randomized, non-comparative Phase II pre-surgical study
• Neo‐Adjuvant Chemotherapy in Patients with Breast Cancer: Retrospective Evaluation of Effectiveness and Tolerability
• Analysis of the predictive value of efficacy of anti‐neoplastic therapies based on the evaluation of molecular pathways associated with tumor stem cells: multi-setting and multi-tumor study. HIERARCHY Study
• Accuracy Diagnostics of Dual‐Energy Digital Mammography (CESM) and Magnetic Resonance Imaging 3 Tesla Compared to Digital Mammography (FFDM) plus Ecography (US) in Detection and Characterization of Mammary Lesions: Results from an OpenStudy Pilot, monocentric, prospective Molecular mechanism of quadruplex targeted drugs: towards clinical candidate selection
• MetORg: a living biobank of human breast cancer metastases